Belite Bio, Inc
BLTE
株式のランク
#3148
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
株価
$143.80
最終同期: 2026-10-16
時価総額
$5.74B
変化（1日）
-5.78%
変化（1年）
63.95%
国
US
取引 Belite Bio, Inc (BLTE)
カテゴリー
Healthcare
Belite Bio, Inc（BLTE）のEPS
June 2026 時点のEPS TTM: $-2.76
Belite Bio, Incの最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-2.76です。2023年末には、EPSは$-1.19で、2022年のEPS$-0.63と増加でした。
Belite Bio, IncのEPS履歴（2020から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-2.76 | 133.90% |
| 2024 | $-1.18 | -0.84% |
| 2023 | $-1.19 | 88.89% |
| 2022 | $-0.63 | 57.50% |
| 2021 | $-0.40 | -35.48% |
| 2020 | $-0.62 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -727.54% |
US
|
|
| $-7.98 | 189.13% |
US
|
|
| $-5.29 | 91.67% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,105.07% |
NL
|
